搜索结果
靶点ID:TCMBANKGE012773
靶点别名:GIF; GLIF; MMIF
靶点描述:macrophage migration inhibitory factor
染色体:22
染色体位置:22q11.23
靶点类型:protein-coding
HERB_ID:-
HGNC_Link:7097
OMIM_Link:153620
Ensembl_Link:ENSG00000240972
靶点对应的植物
| ID | 拉丁名 | 药名 | 药用植物名 | 功能与主治 | 来源 | 药用部位 | 使用民族 |
|---|
靶点对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN013653 | cobalt | Co | 58.93319 g/mol | [Co] | |
| TCMBANKIN027383 | anhydronotoptoloxide | AC1NSXK2; 4-[(E)-3-methyl-4-(3-prop-1-en-2-yloxiran-2-yl)but-2-enoxy]furo[3,2-g]chromen-7-one | C21H20O5 | CC(=C)C1C(O1)CC(=CCOC2=C3C=CC(=O)OC3=CC4=C2C=CO4)C | |
| TCMBANKIN029819 | trypsin | C35H47N7O10 | 725.8 g/mol | CC1=CC(=CC2=C1C=CC(=O)O2)NC(=O)C(CCCN=C(N)N)NC(=O)C(CO)NC(=O)C(CC3=CC=CC=C3)NC(=O)OC(C)(C)C.CC(=O)O | |
| TCMBANKIN033702 | citric acid | InChI=1/C6H8O7/c7-3(8)1-6(13,5(11)12)2-4(9)10/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12; NCGC00090954-02; NCGC00090954-01; HSDB 911; CIT; Citric acid (8CI); BRN 0782061; NCIStruc2_000099; 27109_RIEDEL; AIDS-017733; 1,2,3-PROPANETRICARBOXYLIC ACID,2-HYDROXY (CITRIC ACID); citr; 27488_FLUKA; FEMA No. 2306; E 330; 27485_FLUKA; 27487_FLUKA; 77-92-9; C2404_SIGMA; 2-Hydroxytricarballylic acid; NCIOpen2_004502; F 0001 (polycarboxylic acid); EPA Pesticide Chemical Code 021801; AI3-06286; 245654-34-6; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-; Citretten; Kyselina citronova; 2-hydroxypropane-1,2,3-tricarboxylic acid; Anhydrous citric acid; Citrate standard for IC; C83155_SIAL; LS-2418; WLN: QV1XQVQ1VQ; 1,2,3-Propanetricarboxylic acid, 2-hydroxy- (9CI); NSC30279; .beta.-Hydroxytricarballylic acid; NSC 626579; FLC; NCI60_022579; LS-3185; 2-hydroxy-1,2,3-propanetricarboxylic acid; Caswell No. 221C; EINECS 201-069-1; 43136-35-2; 251275_SIAL; 38730_FLUKA; C4540_SIGMA; FEMA Number 2306; 4-03-00-01272 (Beilstein Handbook Reference); 3-Carboxy-3-hydroxypentane-1,5-dioic acid; Citric acid anhydrous (JAN); C00158; 12262-73-6; 240621_ALDRICH; AIDS017733; MLS001066346; Kyselina 2-hydroxy-1,2,3-propantrikarbonova [Czech]; 2-Hydroxypropanetricarboxylic acid; CCRIS 3292; KBio3_002740; NSC626579; D00037; SBB008922; Kyselina citronova [Czech]; Aciletten; NSC 30279; Anhydrous citric acid (JP15); 46933_SUPELCO; NCIOpen2_004062; Citric acid solution; CHEBI:30769; Citro; BSPBio_003240; NCIStruc1_000057; Uro-trainer; Citric acid, anhydrous (USP); W230618_ALDRICH; Citric acid [USAN:JAN]; H3cit; Chemfill; Hydrocerol A; Suby G; Oprea1_502996; Citric acid, anhydrous; SMR000471840; Citric acid anhydrous; Spectrum3_001850 | C6H8O7 | 192.12 | C(C(=O)O)C(CC(=O)O)(C(=O)O)O |
| TCMBANKIN046097 | dahuribirin d | C32H28O10 | 572.6 g/mol | CC1(C(O1)COC2=C3C=COC3=CC4=C2C=CC5(O4)OC(C(O5)(C)C)COC6=C7C=CC(=O)OC7=CC8=C6C=CO8)C | |
| TCMBANKIN058114 | trans-caffeic acid | 3-(3,4-dihydroxy-phenyl)-acrylic acid; caffeic acid; Caffeate; Lopac-C-0625; 71693-97-5; DivK1c_006624; KBio2_007302; (Z)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; NCGC00015206-02; CAS-3331-39-5; 60020_FLUKA; AI3-63211; 3-(3,4-Dihydroxyphenyl)-2-propenoic acid polymer; (E)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; NSC623438; 4-(2'-Carboxyvinyl)-1,2-dihydroxybenzene; KBio2_004734; (2Z)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; CHEMBL1320034; AIDS-002287; AIDS002287; 501-16-6; CHEBI:36281; Prestwick1_000902; KBio1_001568; 3-(3,4-Dihydroxyphenyl)-2-propenoic acid; AKOS000273846; OR1165; SMR000058214; Spectrum2_001612; 3,4-dihydroxycinnamate; (Z)-3-(3,4-dihydroxyphenyl)acrylic acid; Caffeicacid; KOP; AC1NO658; CCRIS 847; Caffeic acid dehydrogenation homopolymer; SPECTRUM1503987; Spectrum4_001694; SCHEMBL3682144; NCGC00017364-01; NCGC00022654-08; 4-(2-Carboxyethenyl)-1,2-dihydroxybenzene; 78734C5A-1281-44D4-B8A0-A3188AD437E3; cis-Caffeic acid; 3-(3,4-dihydroxyphenyl)acrylic acid; Cinnamic acid, 3,4-dihydroxy-; KBioGR_001988; 3,4-Dihydroxybenzeneacrylic acid; 3,4-dihydroxycinnamic acid; trans-caffeic acid; AIDS-026339; NCGC00015206-01; HSDB 7088; ZINC4482687; (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; 3-(3,4-dihydroxyphenyl)prop-2-enoate; Isocaffeic acid; SBB006475; InChI=1/C9H8O4/c10-7-3-1-6(5-8(7)11)2-4-9(12)13/h1-5,10-11H,(H,12,13)/b4-2; NCGC00017364-02; EU-0100208; C01197; MolPort-001-759-162; KBioSS_002166; Caffeic acid pure; caffeic acid ; trans-Caffeate; (2E)-3-(3,4-dihydroxyphenyl)acrylic acid; NSC 57197; (2E)-3-(3,4-Dihydroxyphenyl)-2-propenoic acid; Spectrum_001686; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)-, (E)-; KBio2_002166; Caffeic acid, cis-; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)-; 3,4-Dihydroxybenzeneacrylate; 3-(3,4-Dihydroxy phenyl)-2-propenoic acid; 4361-87-9; 3,4-Dihydroxy-trans-cinnamate; caffeicacid; AR-360/40806927; EINECS 206-361-2; 60018_FLUKA; Caffeic acid polymer; (E)-3-(3,4-dihydroxyphenyl)acrylic acid; NCGC00022654-04; ZX-AL002121; C0625_SIGMA; SDCCGMLS-0002982.P003; 3-(3,4-Dihydroxyphenyl)-2-propenoic acid, homopolymer; SPBio_001643; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)- (9CI); NCGC00017364-03; 3-(3,4-dihydroxyphenyl)prop-2-enoic acid; AC1LU7RL; SPBio_002943; CHEBI:16433; AIDS026339; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)-, homopolymer; CHEBI:17395; TNP00311; SpecPlus_000528; Prestwick0_000902; MLS000069738; 3,4-dihydroxy-cinnamic acid; 3-(3,4-Dihydroxyphenyl)propenoic acid; NCI60_004400; NSC57197; Caffeic; Lopac-C-0625; NCGC00015206-01; Caffeic acid; cis-Caffeic acid; NCGC00017364-01; (Z)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; C01481; 331-39-5; NCGC00015206-02; CAS-3331-39-5; 3,4-Dihydroxycinnamic acid; CHEBI:17395; (2Z)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; TNP00311; (Z)-3-(3,4-dihydroxyphenyl)acrylic acid; Caffeate; 1- coffee acid | C9H8O4 | 180.16 g/mol | C1=CC(=C(C=C1C=CC(=O)O)O)O |
| TCMBANKIN058519 | (-)-epigallocatechin-3-gallate; (-)-epigallocatechin 3-o-gallate;epigallocatechin gallate; galloyl-l-epigallocatechol; epigallocatechin 3-gallate; (-)-epigallocatechin gallate; | KBio2_000796; SpecPlus_000277; 50299_FLUKA; Spectrum3_000244; KBioGR_002002; 3,4,5-trihydroxybenzoic acid [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] ester; MLS000758300; DivK1c_006373; (−)-Epigallocatechin gallate; EGCG; SPBio_000035; (−)-cis-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-gallate; KBioSS_000796; Epigallocatechin gallate; Spectrum4_001541; (-)-epigallocatechin 3-gallate; Tea catechin; AIDS000674; KBio2_005932; 3,4,5-trihydroxybenzoic acid [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3-chromanyl] ester; KBio1_001317; 989-51-5; AIDS-000674; (2R,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1[2H]-benzopyran-3,5,7-triol-3-(3,4,5-trihydroxybenzoate); KBio2_003364; Galloyl-L-epigallocatechol; SDCCGMLS-0066550.P001; (-)-Epigallocatechol gallate; ACon1_001054; Spectrum5_000102; Green tea extract; MEGxp0_001166; C09731; (-)-Epigallocatechin-3-o-gallate; Epigallocatechin 3-gallate; (-)-Epigallocatechin gallate; CCRIS 3729; Teavigo; [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 3,4,5-trihydroxybenzoate; Spectrum2_000168; Benzoic acid, 3,4,5-trihydroxy-, (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester; (−)-cis-3,3′,4′,5,5′,7-Hexahydroxy-flavane-3-gallate; CHEBI:4806; (-)-epigallocatechin-3-gallate ; (-)-Epigallocatechin gallate (85% (-)-epigallocatechin gallate, 10% (-)-epigallocatechin, 5% (-)- epicatechin gallate); Catechin deriv.; SMR000449288; SPECTRUM210239; E4143_SIAL; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate; Spectrum_000316; (-)-EGCG; KBio3_001128; BSPBio_001628; Epigallocatechol, 3-gallate, (-)-; Epigallocatechin-3-gallate; E4268_SIAL; epigallocatechin gallate ; epigallocatechin-3-gallate; (-)epigallocatechin-3-gallate ; EGCG; 989E515; [5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 2,3,4-trihydroxybenzoate; HMS2051K21; CS-1258; AC1L22IG; AK165605; Green tea polyphenols, Anagen; (-)-Epigallocatechin-3-O-gallate, United States Pharmacopeia (USP) Reference Standard; AKOS015918182; CAS-989-51-5; Epigallocatechin gallate, primary pharmaceutical reference standard; W-5069; (-)-cis-3,3',4',5,5',7-Hexahydroxy-flavane-3-gallate; (-)-Epigallocatechin gallate, analytical standard; Q-100914; DSSTox_RID_78830; AN-15867; DSSTox_GSID_29889; (-)-Epigallocatechol gallate; FT-0604392; NCGC00164319-04; Green tea extract; MEGxp0_001166; (-)-Epigallocatechin-3-o-gallate; Epigallocatechin 3-gallate; N1874; CHEBI:4806; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate; BG00814299; HMS3649E08; D0E9DB; Epigallocatechol, 3-gallate, (-)-; (-)-EpigallocatechinGallateHydrate; Epigallocatechin-3-gallate; AB0014381; BQM438CTEL; NC00078; ST51055716; Epigallocatechin gallate, Pharmaceutical Secondary Standard; Certified Reference Material; SpecPlus_000277; Spectrum3_000244; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl-3,4,5-trihydroxybenzoate; MLS000758300; (-)-Epigallocatechin gallate (EGCG); CCG-38378; Gallic acid, 3-ester with epigallocatechol, (-)-; SR-01000946601-1; NCGC00164319-01; (-)-cis-3,4-Dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-1(2H)-benzopyran-3-yl Gallate; NCGC00164319-06; DSSTox_CID_567; MCULE-3341525983; Epigallocatechin monogallate, B; Tox21_303457; SAM001247031; 4awm; K791; 989-51-5; SR-01000946601; MFCD00075940; EGCG analogs; Galloyl-L-epigallocatechol; NCGC00164319-03; (-)-Epigallocatechin gallate, >=80% (HPLC), from green tea; Spectrum5_000102; CPD000449288; (-)-Epigallocatechin gallate; LMPK12030005; E0694; Teavigo; Epigallocatechin gallate analogs, Anagen; Epigallocatechin-3-monogallate; ACN-035233; Benzoic acid, 3,4,5-trihydroxy-, (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester; Sunphenon; Epigallocatechin gallate(EGCG); s2250; PF-EGCg 90; 3,4-Dihydro-5,7-dihydroxy-2R-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3R-yl-3,4,5-trihydroxybenzoate; 3,4,5-Trihydroxybenzoic acid (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester; MLS001424000; (-)-EGCG; ZINC3870412; KBio2_000796; EGCG cpd; KBioGR_002002; Benzoic acid, 3,4,5-trihydroxy-, 3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester, (2R-cis)-; EGCG, Anagen; NCGC00257243-01; Tox21_201468; L-Epigallocatechin gallate; cid_65064; SPBio_000035; BG01747388; Epigallocatechin gallate; KBioSS_000796; Spectrum4_001541; (-)-epigallocatechin 3-gallate; DB12116; EPIGALOCATECHIN GALLATE; ANTIOXIDANT MODEL (TRAMP) -EPIGALLOCATECHIN GALLATE; KBio2_005932; I14-7747; D0U2BH; MCULE-7760530136; 2kdh; Epigallocatechin gallate, Anagen; AOB2839; SDCCGMLS-0066550.P001; 863-65-0; FR-109; ST097428; ACon1_001054; LS-2197; CCRIS 3729; [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 3,4,5-trihydroxybenzoate; Epigallocate; GTPL7002; BDBM50070942; C22H18O11; GTPs,Anagen; SCHEMBL35258; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; MolPort-001-741-358; DivK1c_006373; KB-206444; SR-01000759328; Teavigo;; EGCG; (-)-EPIGALLOCATECHIN GALLATE (GREEN TEA EXTRACT); HY-13653; (-)-Epigallocatechin gallate, >=95%; NCGC00259019-01; Tea catechin; DS-9030; SR-01000759328-6; SR-01000759328-5; KDH; AC1Q5X0Z; KBio1_001317; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxyb enzoate; (2R,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1[2H]-benzopyran-3,5,7-triol-3-(3,4,5-trihydroxybenzoate); NVP-XAA 723; KBio2_003364; EBD2138593; FT-0082796; NCGC00164319-02; C09731; (-)-cis-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-gallate; UNII-BQM438CTEL; DTXSID1029889; WMBWREPUVVBILR-WIYYLYMNSA-N; [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate; (-)-Epigallocatehin gallate; Spectrum2_000168; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3-yl 3,4,5-trihydroxybenzoate; (-)-Epigallocatechin gallate (85% (-)-epigallocatechin gallate, 10% (-)-epigallocatechin, 5% (-)- epicatechin gallate); Catechin deriv.; SMR000449288; (-)-Epigallocatechin gallat; SPECTRUM210239; Epigallocic acid; Epigallocatcchin Gallate; KS-0000132O; BP-30205; CHEMBL297453; SC-47284; Spectrum_000316; 3oob; (-)-Epigallocatechin gallate, >=97.0% (HPLC); KBio3_001128; BSPBio_001628; epigallo-catechin gallate | C22H18O11 | 458.4g/mol | C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O |
| TCMBANKIN060647 | o-desulfated heparin | C66H93N13O25 | CCC(C)C(C(=O)N1CCCC1C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)CN |
靶点对应的疾病
| 疾病ID | 疾病名 | MeSH名 | HPO名 | UMLS名 | 疾病类型 |
|---|
| TCMBANKDI000011 | Pathological Conditions, Signs and Symptoms | Abnormality of the digestive system; Constitutional symptom | Sign or Symptom | phenotype | |
| TCMBANKDI000023 | Skin and Connective Tissue Diseases; Immune System Diseases | Abnormality of the immune system | Disease or Syndrome | disease | |
| TCMBANKDI000035 | Digestive System Diseases; Infections | - | Disease or Syndrome | disease | |
| TCMBANKDI000049 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI000054 | Nervous System Diseases; Mental Disorders | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI000076 | Neoplasms | - | Neoplastic Process | group | |
| TCMBANKDI000088 | Neoplasms; Respiratory Tract Diseases | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | group | |
| TCMBANKDI000166 | - | - | Neoplastic Process | disease | |
| TCMBANKDI000771 | Skin and Connective Tissue Diseases | Abnormality of the integument; Abnormality of the immune system | Sign or Symptom | phenotype | |
| TCMBANKDI000891 | Neoplasms; Respiratory Tract Diseases | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | disease | |
| TCMBANKDI000935 | Mental Disorders | - | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI001068 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Respiratory Tract Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI001152 | Infections; Respiratory Tract Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI001279 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Cardiovascular Diseases | Abnormality of the nervous system; Abnormality of blood and blood-forming tissues; Abnormality of the cardiovascular system | Disease or Syndrome | disease | |
| TCMBANKDI002297 | Infections | - | Disease or Syndrome | disease | |
| TCMBANKDI002512 | Digestive System Diseases | Abnormality of the digestive system; Abnormality of the immune system | Disease or Syndrome | disease | |
| TCMBANKDI002557 | Eye Diseases; Skin and Connective Tissue Diseases; Musculoskeletal Diseases; Immune System Diseases; Stomatognathic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI002624 | Cardiovascular Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI002742 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | Abnormality of the genitourinary system | Disease or Syndrome | group | |
| TCMBANKDI002974 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI003248 | Nutritional and Metabolic Diseases; Endocrine System Diseases | Abnormality of metabolism/homeostasis; Abnormality of the endocrine system | Disease or Syndrome | disease | |
| TCMBANKDI003353 | Pathological Conditions, Signs and Symptoms; Neoplasms | - | Neoplastic Process | phenotype | |
| TCMBANKDI004039 | Infections | - | Disease or Syndrome | disease | |
| TCMBANKDI004344 | Nervous System Diseases; Endocrine System Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI004508 | Pathological Conditions, Signs and Symptoms; Skin and Connective Tissue Diseases | Abnormality of the integument; Abnormality of connective tissue | Acquired Abnormality | disease | |
| TCMBANKDI004576 | Mental Disorders | - | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI004800 | Infections | - | Disease or Syndrome | group | |
| TCMBANKDI004845 | Pathological Conditions, Signs and Symptoms; Musculoskeletal Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI005098 | Infections; Nervous System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI005503 | Infections | - | Disease or Syndrome | disease | |
| TCMBANKDI005812 | Pathological Conditions, Signs and Symptoms | - | Sign or Symptom | phenotype | |
| TCMBANKDI005930 | Nervous System Diseases; Mental Disorders | - | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI006055 | Pathological Conditions, Signs and Symptoms; Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI006084 | Neoplasms; Nervous System Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI006659 | Immune System Diseases; Cardiovascular Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI006819 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Eye Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI007135 | - | - | Disease or Syndrome | disease | |
| TCMBANKDI007765 | Digestive System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI007782 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI008302 | Mental Disorders | - | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI009080 | Pathological Conditions, Signs and Symptoms; Skin and Connective Tissue Diseases | Abnormality of the integument; Abnormality of head or neck | Disease or Syndrome | disease | |
| TCMBANKDI009231 | Pathological Conditions, Signs and Symptoms; Infections | Abnormality of the immune system | Disease or Syndrome | disease | |
| TCMBANKDI009571 | Cardiovascular Diseases | Abnormality of the cardiovascular system | Disease or Syndrome | disease | |
| TCMBANKDI009773 | Pathological Conditions, Signs and Symptoms; Immune System Diseases; Hemic and Lymphatic Diseases | Abnormality of the immune system; Abnormality of blood and blood-forming tissues | Disease or Syndrome | disease | |
| TCMBANKDI009912 | Pathological Conditions, Signs and Symptoms | Abnormality of metabolism/homeostasis | Sign or Symptom | phenotype | |
| TCMBANKDI009951 | Nutritional and Metabolic Diseases; Musculoskeletal Diseases | Abnormality of the skeletal system | Disease or Syndrome | disease | |
| TCMBANKDI010048 | Infections; Respiratory Tract Diseases | Abnormality of the immune system; Abnormality of the respiratory system | Disease or Syndrome | disease | |
| TCMBANKDI010160 | Respiratory Tract Diseases | Abnormality of the respiratory system | Disease or Syndrome | group | |
| TCMBANKDI010214 | - | - | Neoplastic Process | disease | |
| TCMBANKDI010661 | Nutritional and Metabolic Diseases; Hemic and Lymphatic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI010752 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Skin and Connective Tissue Diseases | - | Disease or Syndrome; Congenital Abnormality | disease | |
| TCMBANKDI011173 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI011393 | Digestive System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI011596 | Skin and Connective Tissue Diseases; Musculoskeletal Diseases; Immune System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI011743 | Neoplasms; Skin and Connective Tissue Diseases | Neoplasm; Abnormality of the breast | Neoplastic Process | group | |
| TCMBANKDI011815 | Digestive System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI011827 | Digestive System Diseases | Abnormality of the digestive system; Abnormality of the immune system | Disease or Syndrome | disease | |
| TCMBANKDI012151 | Respiratory Tract Diseases; Immune System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI013484 | Infections | - | Disease or Syndrome | group | |
| TCMBANKDI013495 | Hemic and Lymphatic Diseases | Neoplasm; Abnormality of blood and blood-forming tissues | Neoplastic Process | group | |
| TCMBANKDI013824 | Mental Disorders | - | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI014088 | Respiratory Tract Diseases; Cardiovascular Diseases | Abnormality of the respiratory system; Abnormality of the cardiovascular system | Disease or Syndrome | disease | |
| TCMBANKDI014244 | Skin and Connective Tissue Diseases; Immune System Diseases; Chemically-Induced Disorders | Abnormality of the integument; Abnormality of the immune system | Disease or Syndrome | disease | |
| TCMBANKDI014368 | Pathological Conditions, Signs and Symptoms | - | Sign or Symptom | phenotype | |
| TCMBANKDI015238 | Musculoskeletal Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI015401 | Infections; Nervous System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI015485 | Mental Disorders | Abnormality of the nervous system | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI015757 | Infections | - | Disease or Syndrome | disease | |
| TCMBANKDI016425 | Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases; Immune System Diseases | Abnormality of the genitourinary system; Abnormality of the immune system | Disease or Syndrome | disease | |
| TCMBANKDI016429 | Skin and Connective Tissue Diseases; Musculoskeletal Diseases; Immune System Diseases | Abnormality of the skeletal system | Disease or Syndrome | disease | |
| TCMBANKDI016612 | Mental Disorders | Abnormality of the nervous system | Mental or Behavioral Dysfunction | phenotype | |
| TCMBANKDI016946 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Digestive System Diseases; Respiratory Tract Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI017024 | Neoplasms; Respiratory Tract Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI017181 | Infections | - | Disease or Syndrome | disease | |
| TCMBANKDI017483 | Neoplasms | - | Neoplastic Process | phenotype | |
| TCMBANKDI017642 | Neoplasms | Abnormality of the integument; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI018016 | Eye Diseases; Skin and Connective Tissue Diseases; Musculoskeletal Diseases; Immune System Diseases; Stomatognathic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI018022 | Pathological Conditions, Signs and Symptoms; Skin and Connective Tissue Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI018565 | Nutritional and Metabolic Diseases; Hemic and Lymphatic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI018680 | Eye Diseases; Immune System Diseases; Endocrine System Diseases | Abnormality of the endocrine system | Disease or Syndrome | disease | |
| TCMBANKDI018992 | Skin and Connective Tissue Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI019825 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI019879 | Digestive System Diseases; Neoplasms; Endocrine System Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI019962 | Infections; Respiratory Tract Diseases | Abnormality of the respiratory system | Disease or Syndrome | group | |
| TCMBANKDI020794 | Nutritional and Metabolic Diseases | Abnormality of metabolism/homeostasis | Disease or Syndrome | disease | |
| TCMBANKDI020911 | Skin and Connective Tissue Diseases; Musculoskeletal Diseases; Immune System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI020997 | Neoplasms; Animal Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI021346 | Otorhinolaryngologic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI022258 | Infections | - | Disease or Syndrome | disease | |
| TCMBANKDI022610 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Digestive System Diseases | Abnormality of the digestive system | Congenital Abnormality | disease | |
| TCMBANKDI022814 | Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI023464 | Nervous System Diseases | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI023498 | Skin and Connective Tissue Diseases; Musculoskeletal Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI024134 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Behavior and Behavior Mechanisms | - | Mental or Behavioral Dysfunction | phenotype | |
| TCMBANKDI024355 | Otorhinolaryngologic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI024535 | Neoplasms; Respiratory Tract Diseases | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | disease | |
| TCMBANKDI025141 | Endocrine System Diseases | Abnormality of the endocrine system; Abnormality of the immune system | Disease or Syndrome | disease | |
| TCMBANKDI025420 | Digestive System Diseases; Neoplasms | Abnormality of the digestive system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI025645 | Infections | - | Disease or Syndrome | disease | |
| TCMBANKDI025727 | Pathological Conditions, Signs and Symptoms | - | Pathologic Function | phenotype | |
| TCMBANKDI025770 | Infections | - | Disease or Syndrome | disease | |
| TCMBANKDI026153 | Digestive System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI026459 | Neoplasms; Respiratory Tract Diseases; Otorhinolaryngologic Diseases | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | disease | |
| TCMBANKDI026782 | Skin and Connective Tissue Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI027354 | Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | Abnormality of the genitourinary system; Abnormality of the immune system | Disease or Syndrome | disease | |
| TCMBANKDI027628 | Pathological Conditions, Signs and Symptoms; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Skin and Connective Tissue Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI027705 | Pathological Conditions, Signs and Symptoms; Infections | - | Pathologic Function | phenotype | |
| TCMBANKDI027908 | Infections | - | Disease or Syndrome | disease | |
| TCMBANKDI028192 | Skin and Connective Tissue Diseases; Immune System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI030204 | - | - | Neoplastic Process | disease | |
| TCMBANKDI030540 | Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Endocrine System Diseases | Abnormality of the genitourinary system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI030664 | Respiratory Tract Diseases | Abnormality of metabolism/homeostasis; Abnormality of the respiratory system | Disease or Syndrome | group | |
| TCMBANKDI031651 | Digestive System Diseases; Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI032115 | Infections | - | Disease or Syndrome | disease |
滇IICP备16009434号-1 |
Dai SX Lab